Veloxis Pharmaceuticals
Corporate Profile
A US pharmaceutical company, Veloxis sells an immunosuppressive drug using proprietary drug delivery technology* to help prevent organ rejection after kidney transplants. Veloxis is enhancing licensing activity to obtain new pharmaceuticals as growth drivers to accelerate the Asahi Kasei Group’s transformation to a global health care enterprise.
- *Technology to enhance the effects and/or reduce the side effects of drugs by controlling their absorption, distribution, metabolism, and excretion
| Trade name | Veloxis Pharmaceuticals, Inc. |
|---|---|
| Main businesses | Research, development, manufacture, and sale of pharmaceuticals for organ transplantation |
| Home office | 2000 Regency Parkway, Suite 500, Cary, NC 27518, USA |
| CEO | Mark E. Hensley |
| Paid-in capital | US$1,117 million (including capital surplus) |
| Shareholder | Asahi Kasei Corp. |
| Phone | +1-919-591-3090 |
(as of April 1, 2023)
Officers & Directors
| Richard A. Packer | Board Director |
|---|---|
| Mark E. Hensley | Chief Executive Officer Board Director |
| Tunde Otulana, MD | Executive Officer Chief Medical Officer |
| Ulf J. Meier-Kriesche, MD | Executive Officer Chief Scientific Officer |
| Ed Sleeper | Executive Officer Chief Ethics and Compliance Officer |
| Stacy G. Wheeler | Executive Officer Senior Vice President, Operations |
| V. Noel Barnard | Executive Officer Vice President, Legal and General Counsel; Secretary |
| Takeshi Ohno | Executive Officer Chief Business Officer |
(as of April 1, 2024)